• Romila Mukerjea, PhD

    Romi joined Scientist.com in early 2018 following a successful stint as Senior Scientist and Group Leader of the recombinant antibody development group at Active Motif. She has a PhD in Molecular Biology from UCSD and has extensive knowledge in structural and functional approaches to the understanding of protein-protein interactions.

  • Kevin Lustig, PhDCEO and Founder

    Kevin is a scientist-entrepreneur with 30 years of research experience in academia and pharma. He co-founded Scientist.com in 2007. In 2001, he co-founded Kalypsys, a small pharmaceutical company. He was Director of Lead Discovery at Tularik from 1997-2001. He carried out postdoctoral work at Harvard Medical School after receiving a PhD degree from Marc Kirschner’s laboratory at UC-San Francisco and an A.B. degree, magna cum laude, from Cornell University.

  • Christopher PetersenCTO and Founder

    Chris is a software engineer who has worked extensively with drug researchers to develop online solutions to complex scientific processes. He co-founded Scientist.com in 2007. From 2002-2006 he was Director of Software Development at Kalypsys, a small pharmaceutical company. He was Director of Engineering at Learning Framework from 1999-2001. Chris received a B.S. degree in Computer Science from Worcester Polytechnic Institute, where he received the Provost’s award.

  • Daniel Kagan, PhDPresident and COO

    Dan is a bioengineer who has worked extensively with life science start-up companies. Prior to joining Scientist.com, he advised startups at eBoost Consulting, started a company called ChemoTactics and was the CTO of the UC-San Diego 100K Entrepreneur Challenge. In 2012, Dan was selected as a Siebel Scholar. Dan received an M.S. and Ph.D in Bioengineering from Joseph Wang’s lab at UCSD, where he was a Gordon Scholar. He received a B.S. degree, summa cum laude, from Rutgers in 2006.

  • Diana Ourthiague, PhDSr. Vice President of Accounts

    Diana Ourthiague, PhD, is a biochemist and SVP of Accounts at Scientist.com, where she oversees a global team that manages marketplace operations and customer service across the platform. Since joining Scientist.com in 2014, Diana has amassed extensive hands-on industry knowledge of the implementation and adoption of research marketplaces at both large and small biopharma companies. Diana received an M.S. and PhD in Biochemistry from the Signaling Systems Lab at UCSD (now at UCLA).

  • Mark HerbertChief Business Officer

    Mark has 20+ years’ experience in pharmaceutical and biotech research across multiple platforms and therapeutic areas. He last served as Interim President of Arcturus Therapeutics. Previously, he was Head of U.S. Business Development at WuXi AppTec. Mark previously served as Director of Pharmaceutical Sciences at Aragon Pharmaceuticals, Inc. which was acquired by Johnson & Johnson in 2013. He is an author or inventor on over 35 peer-reviewed manuscripts and patents and has led or contributed to the submission of 13 investigational new drug (IND) applications and one new drug application (NDA).

  • Kristopher R KaganVice President of Finance

    Kristopher R Kagan is VP of Finance at Scientist.com, where he manages the Finance, Accounting and Human Resources departments and oversees the issuance of all company financial information, including statements, metrics and benchmarks, reporting and analysis and projections and forecasting. Before joining Scientist.com, he worked in corporate finance, where he has over 10 years of experience. Kris received his degree in Finance and Political Science from American University. In 2018, Kris ran for a seat on the Oceanside City Council.

  • Ted J. Torphy PhDChief Science Officer, BioMotiv

    With more than 30 years of experience in pharmaceutical R&D, Ted has been instrumental in the discovery and development of multiple marketed products, including SIMPONI®, STELERA® and SYLVANT®. Since 2004 he has chaired the board of The Cystic Fibrosis Foundation Therapeutics, Inc. During this period the Foundation introduced the venture philanthropy model of co-investing with biotechnology and pharmaceutical companies to bring breakthrough therapies to individuals with cystic fibrosis, including KALYDECO® and ORKAMBITM, the first treatments that correct the fundamental defect causing cystic fibrosis. Ted currently serves as Chief Scientific Officer of BioMotiv, a for-profit drug development accelerator associated with The Harrington Project. Prior to joining BioMotiv Ted spent 12 years with Johnson & Johnson. His roles included Global Head of External Innovation & Business Models for Discovery Sciences, Vice President and Head of External Research and Early Development, Corporate Vice President and Head of Johnson & Johnson’s Corporate Office of Science & Technology, and Senior Vice President and Head of Discovery and Preclinical Development at Centocor, the biopharmaceutical arm of Johnson & Johnson. Prior to joining Johnson & Johnson, Ted spent 17 years with SmithKline Beecham, most recently as Vice President and Head of Biological Research for the Cardiovascular, Metabolic, Pulmonary, Renal and Inflammatory Diseases therapeutic areas. He holds a B.S. degree in Pharmacy from the University of Wisconsin and a Ph.D. in Pharmacology and Toxicology from West Virginia University. He completed his postdoctoral training at the University of California, San Diego.

  • Ray Deshais PhDProfessor & Executive Officer of Biology Caltech

    Dr. Deshaies received his bachelor’s degree in biochemistry from Cornell University and his Ph.D. degree in biochemistry from the University of California, Berkeley. He was a Lucille P. Markey Charitable Trust Postdoctoral Scholar at the University of California, San Francisco. His honors include a Searle Scholar Award, a Beckman Young Investigator Award, a Burroughs Wellcome Fund New Investigator Award in the basic pharmacological sciences, the American Society for Cell Biology–Promega Early Career Life Scientist of the Year Award for 1999, and appointment as a Fellow of the American Association for the Advancement of Science. In 2011, Dr. Deshaies was elected to the American Academy for Arts and Sciences. Deshaies’ lab at Caltech investigates the cellular machinery that mediates protein degradation by the ubiquitin-proteasome system (UPS), and how this machinery regulates cell division. In addition to his academic work, Dr. Deshaies co-founded Proteolix in 2003 with Dr. Craig Crews (Yale), Dr. Susan Molineaux (Calithera), and Dr. Phil Whitcome (deceased). Proteolix initiated development of Kyprolis (approved by FDA, July 2012) and was acquired by Onyx in 2009. Amgen bought Onyx and acquired the rights to Kyprolis in 2013. In 2011, Dr. Deshaies co-founded Cleave Biosciences with Dr. Seth Cohen (UCSD), Dr. Frank Parlati (Calithera), Dr. Peter Thompson (Orbimed Investors), and Dr. Larry Lasky (USVP). Cleave initiated phase I clinical trials in 2014 with a molecular scaffold whose development was initiated in Dr. Deshaies’ laboratory.

  • Randall W. King MDPhD, Professor, Harvard Medical School

    Randall W. King MD, PhD is a Professor in the Department of Cell Biology at Harvard Medical School, where his laboratory develops novel chemical tools to study ubiquitin-dependent protein breakdown and uses high-throughput siRNA screening to identify new genes required for cancer cell division. Prior to joining the faculty at Harvard Medical School, Dr. King was a fellow at the Institute of Chemistry and Cell Biology at Harvard, where he developed new approaches in chemical genetics, including instrumentation used for the synthesis and screening of arrayed split-pool chemical libraries. Dr.King co-founded the drug discovery company Kalypsys in 2001, and served on its science advisory board for four years. He received an MD from Harvard Medical School after receiving a PhD from Mark Kirschner’s laboratory at the University of California, San Francisco (UCSF). He received a B.A. degree in chemistry from Carleton College in 1987.